ASH Clinical News July 2015_updated | Page 74

BACK of the BOOK Heard in the Blogosphere A Cure for ‘Conflict of Interest’ Mania In The Wall Street Journal, researchers criticize the restrictions on research, education, and practice that the conflict-of-interest movement has inspired, which they believe undermine the relationships that drive innovation and, thus, slow medical progress. “The result [of conflict-of-interest culture] is a stifling of honest discourse and potential discouragement of productive collaborations. More strikingly, some of the young, talented physicianinvestigators I spoke with expressed worry about how any industry relationship would affect their careers.” —Lisa Rosenbaum, MD, cardiologist and senior correspondent for The New England Journal of Medicine “The case underlying the conflictof-interest movement is a mixture of moralistic bullying, opinion unsupported by empiric evidence, speculation, simplistic, and distorted interpretations of complicated and nuanced information, superficially and incompletely framed anecdotes, inappropriately extrapolated or irrelevant psychological research results, and emotionally laden human-interest stories.” —Thomas Stossel, MD, senior physician in hematology at Brigham & Women’s Hospital 72 ASH Clinical News High Cost of Cancer Drugs is Unsustainable Clinical Trials Need Cancer Patients “On hearing that I was in a clinical trial, one colleague actually told me that he would rather take his chances with no treatment than be used as ‘a lab rat.’ … I really like to think of myself as the equivalent of a test pilot like Chuck Yeager and the early astronauts. Being a test pilot is a far more romantic, daring and audacious notion than being a lab rat. In the fight against cancer, it’s also more accurate.” —Stan Collender, a patient with a rare skin cancer, in The New York Times Why the Retracted Gay Marriage Study Matters “This retraction is an opportunity to step away from the ‘one bad apple’ framing of scientific misconduct and to seriously examine the features of research and training environments that influence scientists’ behaviors. … In the absence of a reliable way to detect the bad apples in a research community before they commit serious misbehavior, it’s only a matter of time before another case, and another after that.” “We certainly need to consider the pharmaceutical companies’ position in deciding how we’re going to pay for drugs. But, right now, we’re paying for the drug whether it works very well or whether it works just a tiny, little bit. Ultimately, the industry is going to invest in development of drugs because that’s how they’re going to make a living.” —Leonard B. Saltz, MD, on NPR’s “All Things Considered” Conquering Cancer: Personalized Medicine is the Future “Is this revolutionizing everything we know about cancer, from prevention and diagnosis to treatment and recurrence? I would say yes. Testing the genetics of an individual patient has opened up an entire new conversation in oncology leading us to define within the cancer what actually drives its development and progression. … Are we closer to a cure for cancer? I think it’s safe to say we’re closer than ever before.” —David Samadi, MD, discussing precision medicine and genomic testing in The Huffington Post —Janet D. Stemwedel, PhD, in Forbes. The highly publicized study reporting that attitudes toward same-sex marriage could be altered by face-to-face conversations with people who have a stake in the issue was recently retracted by its senior author, after his co-author declined to furnish the raw data he used to reach his conclusions. Follow ASH and ASH Clinical News on: @ASH_Hematology and @ASHClinical News Facebook.com/AmericanSocietyofHematology @ASH_Hematology July 2015